# ABSORB III Randomized Controlled Trial (RCT)

Study · id `cardio:ct-nct01751906` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01751906](<https://clinicaltrials.gov/study/NCT01751906>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01751906

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2008 participants.

## Technical summary

Registry record NCT01751906. Randomized; single masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2018-02-13.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2008 participants (enrolled count; ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Primary completion: 2016-09 (actual) (ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Completion: 2020-10 (actual) (ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Results first posted: 2018-02-13 (ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT01751906, source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01751906-2023-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: ABSORB III Randomized Controlled Trial (RCT)
- Acronym: ABSORB-III
- Condition: Coronary Artery Disease
- Condition: Coronary Artery Stenosis
- Condition: Coronary Disease
- Condition: Coronary Stenosis
- Intervention (Device): Absorb BVS
- Intervention (Device): XIENCE
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial (`cardio:pubmed-28427593`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial (`cardio:pubmed-29100702`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 76b7850b580a3456c040e73e87bfb0e4fc02392e9599898698a03e06e7a7f821
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
